Needham analyst Joseph Stringer maintained a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of $35.00. The company’s shares closed last Wednesday at $28.86.
According to TipRanks.com, Stringer is ranked 0 out of 5 stars with an average return of -11.6% and a 33.0% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Apellis Pharmaceuticals, and Lexicon Pharmaceuticals.
Currently, the analyst consensus on Vir Biotechnology is a Moderate Buy with an average price target of $55.00, which is an 89.1% upside from current levels. In a report issued on July 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $125.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $58.00 and a one-year low of $18.21. Currently, Vir Biotechnology has an average volume of 1.01M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
Read More on VIR:
